Earlier today, the Federal Circuit engaged in rigorous discussion regarding the novelty of a schizophrenia drug patent, which is currently held by Janssen. Teva Pharmaceuticals had previously attempted, without success, to invalidate the patent, questioning the apparent obviousness of the patented substance.
The panel spent their morning session trying to understand the unique aspects of the schizophrenia drug patent. Central to their inquiry was determining what the specific “invention” was in the formulation patented by Janssen. Despite Teva Pharmaceuticals’ arguments, the existing patent’s validity remains unscathed for now. However, the details of the discussions among the panel remain primarily undisclosed.
For those interested in tracking the developments in this ongoing patent dispute, the original report provides further information on the Federal Circuit’s proceedings.